Skip to main content
. 2020 Jul 17;83(10):923–930. doi: 10.1097/JCMA.0000000000000389

Fig. 4.

Fig. 4.

Effect of rosiglitazone (R) alone or combined with bexarotene on the cell growth of BCPAP and follicular thyroid cancer (FTC)-133 cells. A, Thyroid cancer BCPAP cells were treated with 10 μM R alone or in combination with different concentrations of bexarotene (B) under normoxic or hypoxic conditions for 24, 48, and 72 h. Cell growth was analyzed by the MTT assay. *p < 0.05. B, Thyroid cancer FTC-133 cells were treated with 50 μM R alone or in combination with different concentrations of bexarotene (B) under normoxic or hypoxic conditions for 24, 48, and 72 h. Cell growth was analyzed by the MTT assay. *p < 0.05. CTL, control.